Answer
Survanta (beractant) acts biophysically by reducing surface tension and increasing lung compliance, rapidly spreading over alveolar surfaces after intratracheal administration to stabilise alveoli against collapse during breathing and increase alveolar ventilation.
Sources for this answer
- Survanta 25mg/ml suspensionAbbVie Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 14Document updated
Sources checked